These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31444619)

  • 1. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
    Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
    Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
    Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospective practice survey of management of cetuximab-related skin reactions.
    Lugtenberg RT; Boers-Doets CB; Witteveen PO; van Herpen CML; Wymenga ANM; de Groot JWB; Hoeben A; Del Grande C; van Doorn B; Koldenhof JJ; Driessen CML; Gelderblom H
    Support Care Cancer; 2021 Jul; 29(7):3497-3506. PubMed ID: 33150521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
    Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
    Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
    Hofheinz RD; Lorenzen S; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Tetyusheva M; Heeger S; Vlassak S; Merx K
    Ann Oncol; 2018 Apr; 29(4):1010-1015. PubMed ID: 29360920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
    Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
    Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
    Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
    PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
    Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
    Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.
    Belum VR; Marchetti MA; Dusza SW; Cercek A; Kemeny NE; Lacouture ME
    J Am Acad Dermatol; 2017 Sep; 77(3):577-579. PubMed ID: 28807114
    [No Abstract]   [Full Text] [Related]  

  • 13. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?
    Abu-Amna M; Bar-Sela G
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):545-550. PubMed ID: 30547192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K
    Cameli N; Zanniello R; Mariano M; Cristaudo A
    Contact Dermatitis; 2020 Mar; 82(3):189-190. PubMed ID: 31707737
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer.
    Addeo R; Montella L; Mastella A; Vincenzi B; Mazzone S; Ricciardiello F; Del Prete S
    Oncology; 2018; 95(6):353-359. PubMed ID: 30184543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
    Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
    JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
    Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
    J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis.
    Matsuda A; Yamada T; Jamjittrong S; Shinji S; Ohta R; Sonoda H; Kamonvarapitak T; Sekiguchi K; Miyashita M; Suzuki H; Yoshida H
    Anticancer Res; 2020 Jun; 40(6):3469-3476. PubMed ID: 32487646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.